DE69940354D1 - Adenovirus-formulierungen zur gentherapie - Google Patents

Adenovirus-formulierungen zur gentherapie

Info

Publication number
DE69940354D1
DE69940354D1 DE69940354T DE69940354T DE69940354D1 DE 69940354 D1 DE69940354 D1 DE 69940354D1 DE 69940354 T DE69940354 T DE 69940354T DE 69940354 T DE69940354 T DE 69940354T DE 69940354 D1 DE69940354 D1 DE 69940354D1
Authority
DE
Germany
Prior art keywords
infectivity
adenovirus
gene therapy
formulations
adenovirus formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940354T
Other languages
English (en)
Inventor
Shuyuan Zhang
Zheng Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Introgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgen Therapeutics Inc filed Critical Introgen Therapeutics Inc
Application granted granted Critical
Publication of DE69940354D1 publication Critical patent/DE69940354D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69940354T 1998-11-16 1999-11-16 Adenovirus-formulierungen zur gentherapie Expired - Lifetime DE69940354D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10860698P 1998-11-16 1998-11-16
US13311699P 1999-05-07 1999-05-07
PCT/US1999/027177 WO2000029024A1 (en) 1998-11-16 1999-11-16 Formulation of adenovirus for gene therapy

Publications (1)

Publication Number Publication Date
DE69940354D1 true DE69940354D1 (de) 2009-03-12

Family

ID=26806075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940354T Expired - Lifetime DE69940354D1 (de) 1998-11-16 1999-11-16 Adenovirus-formulierungen zur gentherapie

Country Status (8)

Country Link
EP (2) EP1977764A1 (de)
AT (1) ATE421337T1 (de)
AU (1) AU1729600A (de)
CA (1) CA2350890C (de)
DE (1) DE69940354D1 (de)
DK (1) DK1133316T3 (de)
ES (1) ES2323991T3 (de)
WO (1) WO2000029024A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1218035A2 (de) * 1999-09-29 2002-07-03 The Trustees Of The University Of Pennsylvania Schnelle peg-modifikation von virale vektoren
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
GB2408750B (en) * 2003-12-02 2008-12-10 Arthur A Codd Preservation of biological material
DK1780269T3 (da) 2004-02-23 2009-10-12 Crucell Holland Bv Virusrensningsmetoder
ES2357772T3 (es) 2004-06-14 2011-04-29 Ishihara Sangyo Kaisha, Ltd. Composición liofilizada de envuelta viral inactivada con actividad de fusión de membrana.
DE602006003420D1 (de) 2005-04-11 2008-12-11 Crucell Holland Bv Virusreinigung mit ultrafiltration
JP5138601B2 (ja) 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
RU2541784C2 (ru) 2006-11-07 2015-02-20 Санофи Пастер Байолоджикс Ко. Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
KR101504392B1 (ko) 2008-11-03 2015-03-19 크루셀 홀란드 비.브이. 아데노바이러스 벡터의 제조방법
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
CA2795013C (en) 2010-03-31 2018-10-16 Stabilitech Ltd. Stabilisation of viral particles
US20130164296A1 (en) 2010-03-31 2013-06-27 Jeffrey Drew Excipients for Stabilising Viral Particles, Polypeptides or Biological Material
BR112012025044A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd método para conservar adjuvantes de alum e vacinas com adjuvantes de alum
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
DK2825640T3 (en) 2012-03-12 2016-08-01 Crucell Holland Bv BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
CN102755325B (zh) * 2012-07-04 2013-05-29 深圳信立泰药业股份有限公司 一种头孢西丁钠药物组合物、其粉针剂及其制备方法
CN105188745B (zh) 2013-04-25 2019-10-18 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3010931B1 (de) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilisierte lösliche präfusionierte rsv-f-polypeptide
US9974737B2 (en) * 2013-09-19 2018-05-22 Janssen Vaccines & Prevention B.V. Adenovirus formulations
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
JP2018510160A (ja) * 2015-03-20 2018-04-12 ブルーバード バイオ, インコーポレイテッド ベクター製剤
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
CN105219645B (zh) * 2015-11-06 2018-09-25 南京农业大学 一种微生物保护剂及其应用
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JP2019523644A (ja) 2016-05-30 2019-08-29 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された融合前rsv fタンパク質
EP3472327B1 (de) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potenter und ausbalancierter bidirektionaler promotor
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Hpvワクチン
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
CN108703952B (zh) * 2018-08-16 2021-05-07 张志刚 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用
JP2022529002A (ja) * 2019-04-19 2022-06-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
US20220290179A1 (en) * 2019-08-29 2022-09-15 Astellas Pharma Inc. Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
KR20220134622A (ko) 2020-01-31 2022-10-05 베쓰 이스라엘 디코니스 메디칼 센터 인크 코로나바이러스 감염 예방 및 치료용 조성물 및 방법 - sars-cov-2 백신
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥a型肝炎ワクチン
ES2188593T3 (es) * 1992-03-24 2003-07-01 United Cancer Res Inst Vacuna que contiene un virus vivo.
US5994314A (en) * 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
JPH09504429A (ja) * 1993-10-12 1997-05-06 チロン ビアジーン,インコーポレイティド 組換えウイルスの保存方法
JPH09508017A (ja) * 1994-01-12 1997-08-19 ジェネティック セラピー,インコーポレイテッド レトロウイルスベクターの精製
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
EP0968284B1 (de) * 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ID28298A (id) * 1998-02-17 2001-05-10 Schering Corp Komposisi yang mengandung virus dan metode untuk memekatkan preparat-preparat virus

Also Published As

Publication number Publication date
AU1729600A (en) 2000-06-05
CA2350890A1 (en) 2000-05-25
EP1977764A1 (de) 2008-10-08
WO2000029024A9 (en) 2000-11-02
EP1133316A1 (de) 2001-09-19
WO2000029024A1 (en) 2000-05-25
DK1133316T3 (da) 2009-05-25
CA2350890C (en) 2014-07-08
EP1133316B1 (de) 2009-01-21
ES2323991T3 (es) 2009-07-28
ATE421337T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
ATE421337T1 (de) Adenovirus-formulierungen zur gentherapie
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
EA200100337A1 (ru) Стабильные жидкие составы ботулинического токсина
DE69725825D1 (de) 5-HT1F-Agonisten
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
DE69938255D1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
PT1163008E (pt) Utilizacao de trealose para estabilizacao de uma vacina liquida
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BR9815419A (pt) genes desaturase e uso dos mesmos
DE69717815T2 (de) Verbesserungen von kreatin-zusammensetzungen
PT1233784E (pt) Composições e métodos para a estabilização de moléculas biológicas após a liofilização
EE9800248A (et) Külmkuivatatud, vesiikuleid sisaldav ultraheli kontrastaine, selle valmistamismeetod ning ladustamise ja transpordi meetod, ultraheli kontrastaine keskkond ja selle valmistamismeetod ning külmkuivatuse stabilisaatorite kasutamine
DE60126760D1 (de) Vektorkonstrukte
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
BR0007201A (pt) Composições incluindo agentes de preservação demalto-oligossacarìdeos reduzidos, e métodospara preservar um material
WO2022109294A3 (en) Rna stabilization
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
DE69928646D1 (de) Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen
DE69903666D1 (de) Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen
WO1999061039A3 (en) Novel composition for modulating ischemic cell death
WO2000021577A3 (en) Compositions
DE69518319D1 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DE59400836D1 (de) Flüssiggasformulierung zur Vitalitätsprüfung von Zähnen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CRUCELL HOLLAND B.V., LEIDEN, NL